U.S. flag

An official website of the United States government

NM_000488.4(SERPINC1):c.805G>A (p.Glu269Lys) AND not provided

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Dec 30, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003480641.1

Allele description [Variation Report for NM_000488.4(SERPINC1):c.805G>A (p.Glu269Lys)]

NM_000488.4(SERPINC1):c.805G>A (p.Glu269Lys)

Gene:
SERPINC1:serpin family C member 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1q25.1
Genomic location:
Preferred name:
NM_000488.4(SERPINC1):c.805G>A (p.Glu269Lys)
Other names:
p.Glu269Lys
HGVS:
  • NC_000001.11:g.173909900C>T
  • NG_012462.1:g.12479G>A
  • NM_000488.4:c.805G>AMANE SELECT
  • NM_001365052.2:c.661G>A
  • NM_001386302.1:c.928G>A
  • NM_001386303.1:c.886G>A
  • NM_001386304.1:c.784G>A
  • NM_001386305.1:c.763-15G>A
  • NM_001386306.1:c.589G>A
  • NP_000479.1:p.Glu269Lys
  • NP_000479.1:p.Glu269Lys
  • NP_001351981.1:p.Glu221Lys
  • NP_001373231.1:p.Glu310Lys
  • NP_001373232.1:p.Glu296Lys
  • NP_001373233.1:p.Glu262Lys
  • NP_001373235.1:p.Glu197Lys
  • LRG_577t1:c.805G>A
  • LRG_577:g.12479G>A
  • LRG_577p1:p.Glu269Lys
  • NC_000001.10:g.173879038C>T
  • NM_000488.3:c.805G>A
Protein change:
E197K
Links:
dbSNP: rs758087836
NCBI 1000 Genomes Browser:
rs758087836
Molecular consequence:
  • NM_001386305.1:c.763-15G>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000488.4:c.805G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001365052.2:c.661G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001386302.1:c.928G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001386303.1:c.886G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001386304.1:c.784G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001386306.1:c.589G>A - missense variant - [Sequence Ontology: SO:0001583]
Observations:
2

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV004226418Mayo Clinic Laboratories, Mayo Clinic
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Dec 30, 2022)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown2not providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Mayo Clinic Laboratories, Mayo Clinic, SCV004226418.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided2not providednot providedclinical testing PubMed (1)

Description

PP1, PM1, PM2, PS4_supporting

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot provided2not providednot providednot provided

Last Updated: Oct 8, 2024